Cardiolipin Antibody Panel (IgA IgG IgM)

The Cardiolipin Antibody Panel (IgA IgG IgM) detects antibodies that mistakenly target cardiolipin. These antibodies can indicate the presence of autoimmune disorders such as antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), and other conditions that lead to abnormal blood clotting. These antibodies may also be seen temporarily in individuals with acute infections, human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), certain cancers, due to medications (such as phenytoin, penicillin, etc.), or asymptomatically in the elderly.

The Cardiolipin Antibody Panel (IgA IgG IgM) measures IgG, IgM antibodies that help determine the cause of an unexplained thrombotic episode (blood clots), thrombocytopenia (low platelet count), recurrent miscarriage (especially in the second and third trimesters of pregnancy), premature labor, and pre-eclampsia (pregnancy complication characterized by high blood pressure). Testing may be considered in individuals with symptoms suggestive of a thrombotic episode, such as pain and swelling in the extremities, shortness of breath, and headache. This panel can also be done in conjunction with lupus anticoagulant testing as a follow-up to a prolonged clotting time test (activated partial thromboplastin time, or APTT test). Additionally, this panel includes IgA testing, which may be helpful in patients who are negative for IgG and IgM, but still suspected of having APS, especially those with gastrointestinal or mucosal involvement. These antibodies may also appear temporarily during acute infections.

If cardiolipin antibodies are detected initially, the Cardiolipin Antibody Panel (IgA IgG IgM) is repeated 12 weeks later. Re-testing helps determine whether their presence is persistent or temporary. If an individual with an autoimmune disorder tests negative for cardiolipin antibodies, they may be retested later, as these antibodies may develop at any time in the future.

No special preparation is required for this panel. However, individuals should inform their doctor about any medications or supplements that they are taking, as these may affect the test results.

Lab test results may vary across laboratories. Self-medication should be avoided based solely on these results. Always consult a doctor for a proper understanding of the test results. The insights from this test help the doctor tailor appropriate treatment plans to mitigate the risk of clotting, its associated complications.